Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation

Cell and Tissue Research

Volumn 344, Issue 1, 2011, Pages 125-134

  Kuwashiro, Shinya ^a   Terai, Shuji ^a   Oishi, Toshiyuki ^a   Fujisawa, Koichi ^a   Matsumoto, Toshihiko ^a   Nishina, Hiroshi ^b   Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Macrophage; Medaka; Nonalcoholic steatohepatitis; Oryzias latipes (Teleostei); Telmisartan

Indexed keywords

ACYL COENZYME A OXIDASE; ACYL COENZYME A OXIDASE 1; CARNITINE PALMITOYLTRANSFERASE I; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL MODEL; LIPID COMPOSITION; LIPID LIVER LEVEL; LIPID STORAGE; LIVER CELL; MACROPHAGE MIGRATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; ORYZIAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; CARNITINE O-PALMITOYLTRANSFERASE; CELL MOVEMENT; DISEASE MODELS, ANIMAL; FATS; FATTY LIVER; GENE EXPRESSION; HUMANS; MACROPHAGES; ORYZIAS; OXIDATIVE STRESS; PPAR GAMMA; WEIGHT GAIN;

ORYZIAS LATIPES; ORYZIINAE; TELEOSTEI;

EID: 79953829629     PISSN: 0302766X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00441-011-1132-7     Document Type: Article

References (28)

1. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:993-1002 (Pubitemid 38579904)
2. Brunt EM (2001) Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21:3-16
3. Chu YC, Chiu HH (2008) A completely imbedded fish bone presenting as an esophageal tumor-like lesion: an unusual presentation. Gastrointest Endosc 68:1190-1191
4. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ (2003) Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 39:978-983 (Pubitemid 37523769)
5. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues.J Biol Chem 226:497-509
6. Fox ES, Brower JS, Bellezzo JM, Leingang KA (1997) N-acetylcysteine and alpha-tocopherol reverse the inflammatory response in activated rat Kupffer cells. J Immunol 158:5418-5423 (Pubitemid 127681249)
7. Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjoro K, Aukrust P (2006) Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 44:1167-1174
8. Ishibashi M, Hiasa K, Zhao Q, Inoue S, Ohtani K, Kitamoto S, Tsuchihashi M, Sugaya T, Charo IF, Kura S, Tsuzuki T, Ishibashi T, Takeshita A, Egashira K (2004) Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res 94:1203-1210 (Pubitemid 38659633)
9. Jin H, Yamamoto N, Uchida K, Terai S, Sakaida I (2007) Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 364:801-807 (Pubitemid 350103697)
10. Kasahara M, Naruse K, Sasaki S, Nakatani Y, Qu W, Ahsan B, Yamada T, Nagayasu Y, Doi K, Kasai Y, Jindo T, Kobayashi D, Shimada A, Toyoda A, Kuroki Y, Fujiyama A, Sasaki T, Shimizu A, Asakawa S, Shimizu N, Hashimoto S, Yang J, Lee Y, Matsushima K, Sugano S, Sakaizumi M, Narita T, Ohishi K, Haga S, Ohta F, Nomoto H, Nogata K, Morishita T, Endo T, Shin IT, Takeda H, Morishita S, Kohara Y (2007) The medaka draft genome and insights into vertebrate genome evolution. Nature 447:714-719 (Pubitemid 46889726)
11. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321 (Pubitemid 40770284)
12. Kolak M, Westerbacka J, Velagapudi VR, Wagsater D, Yetukuri L, Makkonen J, Rissanen A, Hakkinen AM, Lindell M, Bergholm R, Hamsten A, Eriksson P, Fisher RM, Oresic M, Yki-Jarvinen H (2007) Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 56:1960-1968 (Pubitemid 47195815)
13. Kudo H, Yata Y, Takahara T, Kawai K, Nakayama Y, Kanayama M, Oya T, Morita S, Sasahara M, Mann DA, Sugiyama T (2009) Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int 29:988-996
14. Masahito P, Aoki K, Egami N, Ishikawa T, Sugano H (1989) Lifespan studies on spontaneous tumor development in the medaka (Oryzias latipes). Jpn J Cancer Res 80:1058-1065 (Pubitemid 20032499)
15. Matsumoto T, Terai S, Oishi T, Kuwashiro S, Fujisawa K, Yamamoto N, Fujita Y, Hamamoto Y, Furutani-Seiki M, Nishina H, Sakaida I (2010) Medaka as a model for human nonalcoholic steatohepatitis. Dis Model Mech 3:431-440
16. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419 (Pubitemid 29258890)
17. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74-80 (Pubitemid 20075105)
18. Sadler KC, Amsterdam A, Soroka C, Boyer J, Hopkins N (2005) A genetic screen in zebrafish identifies the mutants vps18, nf2 and foie gras as models of liver disease. Development 132:3561-3572 (Pubitemid 41246129)
19. Sakaida I, Kubota M, Kayano K, Takenaka K, Mori K, Okita K (1994) Prevention of fibrosis reduces enzyme-altered lesions in the rat liver. Carcinogenesis 15:2201-2206 (Pubitemid 24317480)
20. Sanyal AJ (2002) AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123:1705-1725
21. Schaffner F, Thaler H (1986) Nonalcoholic fatty liver disease. Prog Liver Dis 8:283-298
22. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54:3442-3452 (Pubitemid 43334334)
23. Tanaka T, Fukunaga Y, Itoh H, Doi K, Yamashita J, Chun TH, Inoue M, Masatsugu K, Saito T, Sawada N, Sakaguchi S, Arai H, Nakao K (2005) Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator- activated receptor gamma for monocyte recruitment and endothelial regeneration. Eur J Pharmacol 508:255-265 (Pubitemid 40169927)
24. Terai S (2010) Fish model leads to new findings in liver disease. Hepatol Res 40:111-113
25. Watanabe T, Asaka S, Kitagawa D, Saito K, Kurashige R, Sasado T, Morinaga C, Suwa H, Niwa K, Henrich T, Hirose Y, Yasuoka A, Yoda H, Deguchi T, Iwanami N, Kunimatsu S, Osakada M, Loosli F, Quiring R, Carl M, Grabher C, Winkler S, Del Bene F, Wittbrodt J, Abe K, Takahama Y, Takahashi K, Katada T, Nishina H, Kondoh H, Furutani-Seiki M (2004) Mutations affecting liver development and function in medaka, Oryzias latipes, screened by multiple criteria. Mech Dev 121:791-802 (Pubitemid 38813137)
26. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808 (Pubitemid 38063703)
27. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante AW Jr (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116:115-124 (Pubitemid 43121796)
28. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, Rybicki L, McCullough AJ (1998) Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 11:560-565 (Pubitemid 28280720)